Skip to main content

Loading market data...

HALO

Halozyme Therapeutics, Inc.

NASDAQ • United states

$124.37

+$1.87

(+1.53%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Halozyme Therapeutics, Inc. (HALO)

Unavailable

Quotes may be delayed

$14.12B

Market Cap

2,148,955

Volume

34.1

P/E Ratio

Unavailable

Div Yield

Halozyme Therapeutics, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 12390 EL CAMINO REAL, SAN DIEGO, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

1 Oct 2026

Halozyme Therapeutics, Inc. reported A director or senior management change or compensation event

Halozyme Therapeutics, Inc. filed an 8-K covering a director or senior management change or compensation event.

23 Sep 2026

Halozyme Therapeutics, Inc. reported A material agreement

Halozyme Therapeutics, Inc. filed an 8-K covering a material agreement, a material financing obligation, an unregistered sale of shares, supporting financial statements or exhibits.

18 Sep 2026

Halozyme Therapeutics, Inc. reported Another company event

Halozyme Therapeutics, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

17 Sep 2026

Halozyme Therapeutics, Inc. reported Another company event

Halozyme Therapeutics, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.

19 Aug 2026

Halozyme Therapeutics, Inc. reported A director or senior management change or compensation event

Halozyme Therapeutics, Inc. filed an 8-K covering a director or senior management change or compensation event.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$163.14M

Total assets (USD)$2.58B

Total liabilities (USD)$2.43B

Shareholders' equity (USD)$143.54M

Long-term debt (USD)$1.94B

Debt due within a year (USD)$208.97M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$481.00M	$287.65M	$229.91M	$1.90	10-Q · 6 Aug 2026
Q1 2026	$376.71M	$184.52M	$150.05M	$1.22	10-Q · 11 May 2026
Q4 2025	$451.77M	−$92.89M	−$141.59M	Unavailable	10-K · 17 Feb 2026
Q3 2025	$354.26M	$217.92M	$175.23M	$1.43	10-Q · 3 Nov 2025
Q2 2025	$325.72M	$202.44M	$165.16M	$1.33	10-Q · 5 Aug 2025
Q1 2025	$264.86M	$141.54M	$118.10M	$0.93	10-Q · 6 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $105.86

-14.9% upside potential

📈

Strong Buy

Unavailable

👍

Buy

5

⏸️

Hold

2

📉

Sell

0

7 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 11:49 UTC Targets range 78.00–130.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

8

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Option exercise

$18.41 per share

20,000 shares

8

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Open-market sale

$109.40 per share

20,000 shares

7

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Option exercise

$18.41 per share

20,000 shares

7

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Open-market sale

$111.55 per share

20,000 shares

6

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Option exercise

$18.41 per share

20,000 shares

6

Oct 2026

Torley Helen

Director, PRESIDENT AND CEO

Open-market sale

$109.58 per share

20,000 shares

1

Oct 2026

Daly James M

Director

Grant or award

Unavailable per share

1,169 shares

1

Oct 2026

Posard Matthew L.

Director

Open-market sale

$108.54 per share

5,230 shares

16

Sep 2026

Posard Matthew L.

Director

Open-market sale

$107.74 per share

18,996 shares

11

Sep 2026

Torley Helen

Director, PRESIDENT AND CEO

Option exercise

$18.41 per share

20,000 shares

Top Shareholders

Blackrock, Inc.

13,271,095 shares

0.046% change

6/30/2026

Vanguard Group Inc

11,566,896 shares

-0.541% change

12/31/2025

Vanguard Capital Management Llc

5,351,312 shares

1.519% change

6/30/2026

Vanguard Portfolio Management Llc

5,299,008 shares

0.949% change

6/30/2026

State Street Corp

5,179,434 shares

4.892% change

6/30/2026

Invesco Ltd.

3,177,997 shares

-20.797% change

6/30/2026

Morgan Stanley

2,832,594 shares

10.548% change

6/30/2026

Boston Partners

2,773,568 shares

3.349% change

6/30/2026

Bank Of America Corp /De/

2,740,561 shares

-5.923% change

6/30/2026

Geode Capital Management, Llc

2,519,951 shares

0.565% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 11:49 UTC· 19 hours ago

Research coverage and investment tools

Halozyme Therapeutics, Inc. (HALO) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$124.37 on 20 Oct 2026. That is 99% of the way from its 52-week low of US$61.23 to its 52-week high of US$125.10. Its market capitalisation was US$14.12 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$481.00M	$287.65M	$229.91M	$1.90	—	59.8%	$236.72M	10-Q · 6 Aug 2026 (opens in a new tab)
Q1 2026	$376.71M	$184.52M	$150.05M	$1.22	—	49.0%	$176.34M	10-Q · 11 May 2026 (opens in a new tab)
Q4 2025	$451.77M	−$92.89M	−$141.59M	Unavailable	—	-20.6%	$217.60M	10-K · 17 Feb 2026 (opens in a new tab)
Q3 2025	$354.26M	$217.92M	$175.23M	$1.43	—	61.5%	$175.57M	10-Q · 3 Nov 2025 (opens in a new tab)
Q2 2025	$325.72M	$202.44M	$165.16M	$1.33	—	62.2%	$98.15M	10-Q · 5 Aug 2025 (opens in a new tab)
Q1 2025	$264.86M	$141.54M	$118.10M	$0.93	—	53.4%	$153.27M	10-Q · 6 May 2025 (opens in a new tab)

Cash and equivalents: $163.14M
Total assets: $2.58B
Total liabilities: $2.43B
Shareholders' equity: $143.54M
Long-term debt: $1.94B
Debt due within a year: $208.97M

8-K · 1 Oct 2026 · Management change

Halozyme Therapeutics, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Halozyme Therapeutics, Inc. filed an 8-K covering a director or senior management change or compensation event.
8-K · 23 Sep 2026 · Material agreement Signed

Halozyme Therapeutics, Inc. reported A material agreement (opens in a new tab)

Halozyme Therapeutics, Inc. filed an 8-K covering a material agreement, a material financing obligation, an unregistered sale of shares, supporting financial statements or exhibits.
8-K · 18 Sep 2026

Halozyme Therapeutics, Inc. reported Another company event (opens in a new tab)

Halozyme Therapeutics, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 17 Sep 2026

Halozyme Therapeutics, Inc. reported Another company event (opens in a new tab)

Halozyme Therapeutics, Inc. filed an 8-K covering another company event, supporting financial statements or exhibits.
8-K · 19 Aug 2026 · Management change

Halozyme Therapeutics, Inc. reported A director or senior management change or compensation event (opens in a new tab)

Halozyme Therapeutics, Inc. filed an 8-K covering a director or senior management change or compensation event.

Insider	Date	Transaction	Shares	Average price	Filing
Torley Helen Director, PRESIDENT AND CEO	8 Oct 2026	Option exercise (M)	+20,000	$18.41	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	8 Oct 2026	Open-market sale (S)	−20,000	$109.40	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	7 Oct 2026	Option exercise (M)	+20,000	$18.41	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	7 Oct 2026	Open-market sale (S)	−20,000	$111.55	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	6 Oct 2026	Option exercise (M)	+20,000	$18.41	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	6 Oct 2026	Open-market sale (S)	−20,000	$109.58	Form 4 (opens in a new tab)
Daly James M Director	1 Oct 2026	Grant or award (A)	+1,169	—	Form 4 (opens in a new tab)
Posard Matthew L. Director	1 Oct 2026	Open-market sale (S)	−5,230	$108.54	Form 4 (opens in a new tab)
Posard Matthew L. Director	16 Sep 2026	Open-market sale (S)	−18,996	$107.74	Form 4 (opens in a new tab)
Torley Helen Director, PRESIDENT AND CEO	11 Sep 2026	Option exercise (M)	+20,000	$18.41	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	13,271,095	0.046%
Vanguard Group Inc	12/31/2025	11,566,896	-0.541%
Vanguard Capital Management Llc	6/30/2026	5,351,312	1.519%
Vanguard Portfolio Management Llc	6/30/2026	5,299,008	0.949%
State Street Corp	6/30/2026	5,179,434	4.892%
Invesco Ltd.	6/30/2026	3,177,997	-20.797%
Morgan Stanley	6/30/2026	2,832,594	10.548%
Boston Partners	6/30/2026	2,773,568	3.349%
Bank Of America Corp /De/	6/30/2026	2,740,561	-5.923%
Geode Capital Management, Llc	6/30/2026	2,519,951	0.565%

Previous close: 122.50 USD
Day range: 123.00 – 125.10 USD
52-week range: 61.23 – 125.10 USD
Volume: 2,148,955
Market cap: $14.12B
Average volume: 2,187,307
P/E ratio: 34.1
EPS (FY 2025, diluted): 2.56 USD
Shares outstanding: 113.50M
Beta (5Y monthly): 0.93

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:21 UTC· 54 minutes ago

P/E is market cap ÷ trailing 12-month net income from SEC filings.

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for HALO yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.